Real-world effectiveness and safety of xanomeline and trospium for treatment-resistant schizophrenia in a state hospital system
In inpatients with TRS taking adjunct DRBAs (including anticholinergic DRBAs) XT use was commonly discontinued due to intolerability/ineffectiveness. Larger controlled trials are needed to further investigate XT's effectiveness for treating TRS and determine how adjunct anticholinergic use impacts its safety/efficacy.
Authors
- Nina Vadiei (ORCID: https://orcid.org/0000-0003-3984-0317)
- M. Lynn Crismon
Institutions
- Austin College (US)
- The University of Texas at San Antonio Health Science Center (US)
- State Hospital (GB)
- San Antonio State Chest Hospital (US)
- The University of Texas at Austin (US)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Frontiers in Psychiatry
- Published
- 2026-01-30
- DOI
- https://doi.org/10.3389/fpsyt.2025.1736922
- Citations
- 1
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 33.12